Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 232

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 232
---
 the valid and enforceable patents and proprietary rights of other parties. As of the date hereof, we are the patentee of a number of provisional and non -provisionalpatent applications, both on our proprietarily developed projects and improvement to our in -licensedprojects. The following table sets forth a list of our patent rights under the exclusive licenses as of the date hereof related to our Lead Project, ALS -4; our other Lead Project, SACT -1is a proprietary technology not subject to any license agreement:

| Project         
 Company/Project 
 name            |     | License                                                             
 Agreement                                                           |     | Licensor(s)       |     | Licensee                       |     | Licensed/IP Rights                                                                                            |     | Patent Expiration                                                                                                                               
 Dates                                                                                                                                           |
| Acticule/ALS-4  |     | Exclusive Patent License Agreement, dated October 18, 2017          
 First Amendment to Exclusive License Agreement, dated June 7, 2018  
 Second Amendment to Exclusive License Agreement dated July 10, 2019 
 Exclusive Patent License Agreement dated January 11, 2019           |     | Versitech Limited |     | Acticule Life Sciences Limited |     | Exclusive licensee: 2 pending U.S. applications (16/867,540 and 17/006,985), 2 pending applications in Canada |     | The licensed IP rights include granted patents in the U.S. and pending patent applications in the U.S., and Canada.                             
 The U.S. patents will expire in 2038; any other patent based on the pending application, if granted, will have a 20-year patent term from 2018. |

Because of the extensive time required for clinical development and regulatory review of a drug we may develop, it is possible that, before any of our drug candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of any such patent. If appropriate, the Company may seek to extend the period during which it has exclusive rights to a product by pursuing patent term extensions and marketing exclusivity periods that are available from the regulatory authorities of certain countries (including the United States) and the EPO. Even though the Company has certain patent rights, the ability to obtain and maintain protection of biotechnology and pharmaceutical products and processes such as those we intend to develop and commercialize involves complex legal and factual questions. No consistent policy regarding the breadth of claims allowed in such patents has emerged to date